The designation applies to the use of a therapeutic device for degenerative disc disease in transforaminal lumbar interbody fusion.
“The technology that Amphix Bio is developing could offer several critical advantages compared to products currently available for TLIF spine surgeries,” Wellington Hsu, MD, a clinical advisor for Amphix Bio, said in the release. “The moldability of the material will enable surgeons to easily apply it in various surgical settings and challenging anatomies, and the implant can induce bone growth without the use of donor tissue or recombinant proteins. All these factors could make this a safer, simpler, and more effective bone graft for spinal fusion.”
Breakthrough device designation will help accelerate the development, assessment and review for Amphix Bio’s biologic.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
